Abstract
Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Current Drug Safety
Title: Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Volume: 3 Issue: 1
Author(s): Luis Garcia-Marcos, Jose A. Ros-Lucas and Manuel Sanchez-Solis
Affiliation:
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Abstract: Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Export Options
About this article
Cite this article as:
Garcia-Marcos Luis, Ros-Lucas A. Jose and Sanchez-Solis Manuel, Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783334005
DOI https://dx.doi.org/10.2174/157488608783334005 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews Advances in Noninvasive Pulmonary Gene Therapy
Current Drug Delivery Novel Biological Therapies in Severe Asthma: Targeting the Right Trait
Current Medicinal Chemistry Expression, Purification, and Immunological Characterization of Cr PI
Protein & Peptide Letters Novel Strategies for the Treatment of Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Short Term, Low Dose Simvastatin Pretreatment Alters Memory Immune Function Following Secondary Staphylococcus aureus Infection
Current Pharmaceutical Biotechnology Phylogeny and Genetic Code: Evolution and Conservation
Current Pharmaceutical Design Dynamics of CD86 Expression on Allergic Inflammation - New Insights
Recent Patents on Inflammation & Allergy Drug Discovery Immune Mechanisms of Sublingual Immunotherapy and Mycobacterial Adjuvants in the Treatment of Allergic Disease
Current Immunology Reviews (Discontinued) Inflammation, Allergy and Asthma, Complex Immune Origin Diseases: Mechanisms and Therapeutic Agents
Recent Patents on Inflammation & Allergy Drug Discovery Burner Development for the Reduction of NOx Emissions from Coal Fired Electric Utilities
Recent Patents on Mechanical Engineering Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Silver Based Materials for Biomedical Applications
Current Organic Chemistry Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery